CHELSEA KAUFFMAN: Open Payments
NPI 1124556832 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$407 in 21 payments from 9 companies in 2025. Trend: 2023 $372 · 2024 $30 · 2025 $407
Food & beverage: $407
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 4 | $81 |
| Sage Therapeutics, LLC | 3 | $69 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $59 |
| MAYNE PHARMA COMMERCIAL LLC | 3 | $52 |
| Exeltis, USA Inc. | 2 | $43 |
| Astellas Pharma US Inc | 1 | $34 |
| Evofem Biosciences, Inc. | 4 | $25 |
| Supernus Pharmaceuticals, Inc. | 1 | $23 |
| CooperSurgical, Inc. | 1 | $21 |
Products named: LILETTA, ZURZUVAE, SLYND, Veozah, Mirena, Kyleena, Phexxi, Qelbree.
Industry payments across CA — which companies pay providers there.
